Related Experiment Video
Updated: Jun 10, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation
Marisa Chang1, Nisha Kanwar, Eric Feng
1Genetics and Development Division, Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.
Molecular Cancer Therapeutics
|July 30, 2010
Summary
A novel compound, M-110, selectively inhibits PIM-3 kinase, a key regulator of STAT3 signaling. This PIM-3 inhibition reduces cancer cell proliferation by downregulating activated STAT3 (pSTAT3(Tyr705)).
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- Identifying novel small molecules for cancer therapy is crucial.
- The PIM kinase family and STAT3 signaling pathway are implicated in cancer cell proliferation.
- Understanding the specific roles of PIM kinases in cancer is an active area of research.
Purpose of the Study:
- To identify and characterize novel small chemical compounds that inhibit cancer cell growth.
- To elucidate the molecular mechanism by which the identified compound M-110 affects cancer cell signaling.
- To investigate the role of PIM kinases in regulating STAT3 phosphorylation.
Main Methods:
- High-throughput screening of chemical compounds for anti-proliferative activity against cancer cells.
- Kinase screening to identify the molecular target of compound M-110.
- Western blotting and siRNA knockdown experiments to analyze STAT3 and PIM kinase interactions.
- Cell proliferation assays to determine IC50 values and specificity.
Main Results:
- Compound M-110 selectively inhibits PIM kinase family members, with a preference for PIM-3.
- M-110 treatment significantly reduces the phosphorylation of STAT3 (pSTAT3(Tyr705)) in prostate and pancreatic cancer cell lines.
- Knockdown of PIM-3, but not PIM-1 or PIM-2, leads to downregulation of pSTAT3(Tyr705).
- M-110 demonstrates no activity against normal human peripheral blood mononuclear cells.
Conclusions:
- PIM-3 kinase is identified as a novel positive regulator of STAT3 signaling.
- Inhibition of PIM-3 kinase by M-110 leads to the downregulation of pSTAT3(Tyr705) and subsequent cancer cell growth inhibition.
- M-110 represents a promising therapeutic candidate for cancers driven by PIM-3/STAT3 signaling.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...